Article
Gastrointestinal Stromal Tumor: Current Approaches and Future Directions in the Treatment of Advanced Disease.
Hematology/oncology clinics of North America - 1 Aug 2025
Cicala Carlo M, Bauer Sebastian, Heinrich Michael C, Serrano César
Abstract excerpt
This review discusses the current and future landscape of advanced gastrointestinal stromal tumor (GIST) treatment. It covers the role of tyrosine kinase inhibitors (TKIs), specifically imatinib, and further treatment options, such as sunitinib, regorafenib, and ripretinib, as well as avapritinib for platelet-derived growth factor receptor alpha D842V mutations. In addition, this review emphasizes individualized...
Topics
- Humans
- Gastrointestinal Stromal Tumors
- Protein Kinase Inhibitors
- Gastrointestinal Neoplasms
- Mutation
- Molecular Targeted Therapy
- Proto-Oncogene Proteins c-kit
- Antineoplastic Agents
- Imatinib Mesylate
